An observational study in Acute-On-Chronic Liver Failure, sponsored by Zagazig University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2018-08-14.
Sponsored by Zagazig University · Observational
Rationale:
To identify the prevalence of Acute-on-chronic liver failure in Zagazig University Hospitals.
The question of the research:
How much the prevalence of Acute-on-chronic Liver Failure in Zagazig University Hospitals?
The aim of the work:
The aim of the study is to identify the presence of Acute-on-chronic Liver Failure in Zagazig University Hospitals
Objectives:
To estimate the prevalence of Acute-on-chronic Liver Failure in Zagazig University Hospitals.
Subjects and Methods:
I . Technical Design:
II . OPERATIONAL DESIGN:
III. Administrative Design:
Results:
Collected data will be presented in tables and suitable graphs and analyzed according to standard statistical methods
445 studies on the registry are indexed under Liver Failure; 69 are open to participants now.
This study's enrollment of 300 is above the median of 129 across 146 observational studies indexed under Liver Failure.
Browse Liver Failure studies →Zagazig University is the lead sponsor of 447 studies on the registry; 75 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
All patients admitted to Gastroenterology and Hepatology Unit with the criteria of ACLF according to EASL-AASLD will be included in this study.
Exclusion Criteria:
improvement of the patients score according to SOFA score (AASLD and EASL guidelines)
follow up of participants until the patients recover
Time frame: 24 weeks from first recruiting
death of the patient
due to the severity of acute on chronic failure, the death of patients is expected
Time frame: 24 weeks from first recruiting
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zagazig University